menu
    • menu

    Company profile for Kyverna Therapeutics

    NEW Drugs in Dev: 2
    Farmak works in the development, production and marketing of APIs, Intermediates & Specialties// FDA inspected.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    IKF/Pharmasynthese have been with fine chemicals market and APIs performance for more than 40 years.

    Virtual Booth

    Contact Supplier

    Cosma S.p.A., part of CFM Group with AMSA & Clarochem, provides global pharma & veterinary health with 300+ tons of FDA-approved APIs.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    We are a cell therapy company developing a new class of treatments and potential cures for serious autoimmune diseases. Autoimmune diseases result from a failure of the immune system to distinguish self from non-self, caused by autoreactive B cells and T cells attacking the body’s own tissues. Kyverna’s therapeutic strategy combines advanced T cell engineering and synthetic biology technologies to suppress and eliminate th...
    We are a cell therapy company developing a new class of treatments and potential cures for serious autoimmune diseases. Autoimmune diseases result from a failure of the immune system to distinguish self from non-self, caused by autoreactive B cells and T cells attacking the body’s own tissues. Kyverna’s therapeutic strategy combines advanced T cell engineering and synthetic biology technologies to suppress and eliminate these autoreactive immune cells at the root cause of inflammatory disease.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Kyverna TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    740 Heinz Avenue Berkeley, CA 94710
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://kyvernatx.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/kyverna/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    SCOPE Summit

    SCOPE Summit

    Not Confirmed

    envelop Contact Supplier

    SCOPE Summit

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Kyverna Updates Corporate Strategy At J.P. Morgan Conference
    Kyverna Updates Corporate Strategy At J.P. Morgan Conference

    12 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/12/3216812/0/en/Kyverna-Therapeutics-Provides-Corporate-Update-and-Outlines-2026-Strategic-Priorities-at-the-J-P-Morgan-Healthcare-Conference.html

    GLOBENEWSWIRE
    12 Jan 2026
    Share Share
    Kyverna Therapeutics at 2026 J.P. Morgan Healthcare Conference
    Kyverna Therapeutics at 2026 J.P. Morgan Healthcare Conference

    05 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/05/3212695/0/en/Kyverna-Therapeutics-to-Present-at-the-J-P-Morgan-2026-Healthcare-Conference.html

    GLOBENEWSWIRE
    05 Jan 2026
    Share Share
    Kyverna Therapeutics Prices $100M Public Stock Offering
    Kyverna Therapeutics Prices $100M Public Stock Offering

    17 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/17/3207060/0/en/Kyverna-Therapeutics-Announces-Pricing-of-100-Million-Public-Offering-of-Common-Stock.html

    GLOBENEWSWIRE
    17 Dec 2025
    Share Share
    Kyverna Therapeutics Reports Positive KYSA-8 Trial Results
    Kyverna Therapeutics Reports Positive KYSA-8 Trial Results

    15 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/15/3205250/0/en/Kyverna-Therapeutics-Announces-Positive-Topline-Data-from-Registrational-KYSA-8-Trial-of-Miv-cel-KYV-101-in-Stiff-Person-Syndrome.html

    GLOBENEWSWIRE
    15 Dec 2025
    Share Share
    Kyverna Therapeutics Announces Proposed Stock Offering
    Kyverna Therapeutics Announces Proposed Stock Offering

    15 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/15/3205833/0/en/Kyverna-Therapeutics-Announces-Proposed-Public-Offering-of-Common-Stock.html

    GLOBENEWSWIRE
    15 Dec 2025
    Share Share
    Kyverna Therapeutics To Release KYV-101 Phase 2 Trial Results
    Kyverna Therapeutics To Release KYV-101 Phase 2 Trial Results

    14 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/14/3205067/0/en/Kyverna-Therapeutics-to-Report-Topline-Results-from-Registrational-Phase-2-KYSA-8-Trial-of-KYV-101-in-Stiff-Person-Syndrome.html

    GLOBENEWSWIRE
    14 Dec 2025
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search